英文互译镜像站

Depatuxizumab mafodotin

Last updated
Depatuxizumab mafodotin
Mafodotin ADCs.svg
Monoclonal antibody
Type Whole antibody
Source Chimeric/humanized hybrid (mouse/human)
Target EGFR
Clinical data
Other namesABT-414
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6624H10228N1728O2052S42
Molar mass 148251.25 g·mol−1

Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. [1] [2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. [3] [4]

This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma. [5]

In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme. [6] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors. [7] Phase I results were presented at ASCO in 2016. [7]

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association .
  2. ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  3. ↑ "Antibody-drug conjugates in the spotlight - The Antibody Society". antibodysociety.org. 14 October 2016. Archived from the original on 22 December 2016. Retrieved 13 December 2016.
  4. ↑ Nagayama A, Ellisen LW, Chabner B, Bardia A (December 2017). "Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments". Targeted Oncology. 12 (6): 719–739. doi:10.1007/s11523-017-0535-0. PMID   29116596. S2CID   1012740.
  5. ↑ "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019". abbvie.com. Retrieved 20 May 2019.
  6. ↑ "Depatuxizumab mafodotin". en.pharmacodia.com. Archived from the original on 2016-12-20. Retrieved 2016-12-13.
  7. 1 2 "Depatuxizumab mafodotin - AbbVie - AdisInsight". adisinsight.springer.com.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
MirrorElf 递归网站下载 YES镜站站群引擎 网站复制工具 关键词转码站群